Skip to main content
. Author manuscript; available in PMC: 2013 Dec 15.
Published in final edited form as: Clin Cancer Res. 2012 Oct 2;18(24):6758–6770. doi: 10.1158/1078-0432.CCR-12-1177

Fig. 2. Waterfall plot of percent change in measureable tumor burden in all treated patients (n=31).

Fig. 2

The patients were treated between August 23, 2007 and October 6, 2010. Clinical responses were evaluated using the irRC criteria from whole body CT scans, as described in the Materials and Methods section. The percent change in tumor burden using the best overall irRC response after TIL infusion is shown for all patients. The dotted line indicates the −50% tumor burden reduction point needed to reach an objective clinical response according to irRC. Of the 15 patients who responded, 12 had ≥70% reduction in their tumor burden and 4 patients had a 100% reduction in measureable tumor burden. Two patients had non-measureable bony lesions that remained stable throughout the study period. This was not accounted for in determining the change in tumor burden shown.